Organization | Biotrial

Biotrial Report issue

For profit Phase 1 Phase 2

Founded: Rennes France (1989)

Organization Overview

First Clinical Trial

2007

NCT01520727

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Biotrial | BIOTRIAL | Biotrial, 7-9, rue Jean-Louis Bertrand, F-35000 Rennes, France | Biotrial - Human Pharmacology Unit | Biotrial Inc. | Biotrial Rennes

Active Ingredients

Drugs in Phase 2 Trials (2)

exs21546 (1 trial)

sqy51 (1 trial)

Drugs in Phase 1 Trials (15)

aef0117 (2 trials)

anagrelide (agrylin) (1 trial)

ant3310 (1 trial)

ath-1017 (1 trial)

ath-1020 (1 trial)

bevacizumab (avastin) (1 trial)

binimetinib (mektovi) (2 trials)

denosumab (prolia) (2 trials)

eslicarbazepine acetate (aptiom) (1 trial)

meropenem (merrem) (1 trial)

moxifloxacin (avelox) (2 trials)

opicapone (Ongentys) (5 trials)

rasagiline (azilect) (2 trials)

simvastatin (zocor) (1 trial)

ustekinumab (stelara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alzheimer Disease (Phase 1)

Epilepsy (Phase 1)

Parkinson Disease (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 19
# of Trial APIs: 17